Certara Scientists are Among the Topmost Cited Biopharma Researchers

Certara celebrates its 200 published papers and 11 scientists on Stanford/Elsevier top 2% cited researchers list in 2025

Certara has maintained its leadership in the multidisciplinary field of pharmacology and pharmacokinetics since the inaugural list. This year, the following Certara researchers appeared on Elsevier’s top 2% of the world’s most-cited researchers list either for the single calendar year 2024 or over the span of their entire career:

• Amin Rostami-Hodjegan, SVP of R&D and Chief Scientific Officer
• Hannah Jones, SVP, Head of Simcyp PBPK Modeling Services
• Hugo Geerts, Head of Neuroscience Modeling, QSP
• Karen Rowland Yeo, SVP, Client & Regulatory Strategy
• Khaled Abduljalil, Senior Principal Scientist
• Masoud Jamei, SVP, Simcyp R&D
• Patrick F. Smith, SVP, Translational Science
• Piet van der Graaf, SVP and Head of Quantitative Systems Pharmacology
• Rajesh Krishna, Senior Distinguished Scientist, Drug Development Solutions
• Stephen Duffull, Senior Scientific Advisor, Quantitative Science Services
• Trevor Johnson, Principal Scientist

Rostami-Hodjegan was also awarded the 2025 Lewis B. Sheiner Lecturer Award by the International Society of Pharmacometrics (ISoP), which recognizes the lifetime achievements of a distinguished scientist for excellence and innovation in pharmacometric research. As the co-founder of the Simcyp Simulator®, Rostami-Hodjegan’s approach to innovation and research is clear in the product’s outcomes. The Simcyp Simulator is currently used by more than 11 global regulatory agencies and has supported over 120 FDA-approved drugs in lieu of clinical studies. In addition, the Simcyp Consortium – a collaborative group of members from 35 leading biopharmaceutical companies that guides the development of the Simulator – is the longest-standing consortium of its kind and has become a global authority on mechanistic PBPK modeling and simulation.

New approach methodologies (NAMs) like the Simcyp Simulator are especially critical now as the biopharma industry moves to phase out animal testing, as outlined by the FDA and NIH earlier this year. PBPK modeling will continue to be at the forefront of reducing the use of animals in pre-clinical research, an effort Certara has been advancing for the last 25 years.

To learn more about how our experts are leading the pharmaceutical industry’s transition away from animal testing, please read our recent article in STAT.